TRIPASS XR تري باس

 

Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol.

2009;27(29):4839–4847.

Blom JW et al. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record

linkage study. J Thromb Haemost. 2006;4(3):529–535.

Trousseau A. Phlegmasia Alba Dolens. Clinique Medicale de l’Hotel Dieu. Vol 3. London: The New Sydenham

Society; 1865.

Aderka D et al. Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult

cancer. Cancer. 1986;57(9):1846–1849.

Goldberg RJ et al. Occult malignant neoplasm in patients with deep venous thrombosis. Arch Intern Med.

1987;147(2):251–253.

Sanz MA, Montesinos P. Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb Res.

2010;125 Suppl 2:S51–S54.

Stein E et al. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol.

2009;22(1):153–163.

Oppelt P et al. Approach to chemotherapy-associated thrombosis. Vasc Med. 2015;20(2):153–161.

Palumbo A et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia.

2008;22(2):414–423.

Zangari M et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for

therapy. Blood. 2002;100(4):1168–1171.

Knight R et al. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med. 2006;354(19):2079–

2080.

Skillings JR. Arterial thromboembolic events in a pooled analysis of 5 randomized, controlled trials of bevacizumab

with chemotherapy. J Clin Oncol. 2005;23(Suppl):16S.

Johnson DH et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with

carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung

cancer. J Clin Oncol. 2004;22(11):2184–2191.

Zangari M et al. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol.

2009;27(29):4865–4873.

Khorana AA et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of

major guidelines panels and call to action. J Clin Oncol. 2009;27(29):4919–4926.

Lyman GH et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society

of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654–656.

Lindley CM et al. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient

oncology population. J Clin Oncol. 1989;7(8):1142–1149.

Sonis ST et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology,

and consequences for patients. Cancer. 2004;100(9, Suppl):1995–2025.

Garden AS, Chambers MS. Head and neck radiation and mucositis. Curr Opin Support Palliat Care.

2007;1(1):30–34.

Lalla RV et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer

therapy. Cancer. 2014;120(10):1453–1461.

Epstein JB et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA

Cancer J Clin. 2012;62(6):400–422.

Dirix P et al. Radiation-induced xerostomia in patients with head and neck cancer: a literature review. Cancer.

2006;107(11):2525–2534.

Hensley ML et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of

chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27(1):127–145.

Johnson JT et al. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N EnglJ

Med. 1993;329(6):390–395.

Momm F et al. Different saliva substitutes for treatment of xerostomia following radiotherapy. A prospective

crossover study. Strahlenther Onkol. 2005;181(4):231–236.

Kam MK et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in

early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25(31):4873–4879.

Aguiar GP et al. A review of the biological and clinical aspects of radiation caries. J Contemp Dent Pract.

2009;10(4):83–89.

Sonis ST. Oral mucositis in cancer therapy. J Support Oncol. 2004;2(6 Suppl 3):3–8.

Martins F et al. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol.

2013;49(4):293–298.

Gelclair [product information]. www.gelclair.com. Helsinn Healthcare SA L, Switzerland. Accessed August 1,

2015.

Barber C et al. Comparing pain control and ability to eat and drink with standard therapy vs Gelclair: a

preliminary, double centre, randomised controlled trial on patients with radiotherapy-induced oral mucositis.

Support Care Cancer. 2007;15(4):427–440.

Mahood DJ et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol. 1991;9(3):449–

452.

Ferretti GA et al. Chlorhexidine for prophylaxis against oral infections and associated complications in patients

receiving bone marrow transplants. J Am Dent Assoc. 1987;114(4):461–467.

Ferretti GA et al. Chlorhexidine prophylaxis for chemotherapy- and radiotherapy-induced stomatitis: a randomized

double-blind trial. Oral Surg Oral Med Oral Pathol. 1990;69(3):331–338.

Shaw MT et al. Effects of cancer, radiotherapy and cytotoxic drugs on intestinal structure and function. Cancer

Treat Rev. 1979;6(3):141–151.

Wurth MA, Musacchia XJ. Mechlorethamine effects on intestinal absorption in vitro and on cell proliferation. Am

J Physiol. 1973;225(1):73–80.

Roche AC et al. Correlation between the histological changes and glucose intestinal absorption following a single

dose of 5 fluorouracil. Digestion. 1970;3(4):195–212.

Pessi MA et al. Targeted therapy-induced diarrhea: A review of the literature. Crit Rev Oncol Hematol.

2014;90(2):165–179.

Irinotecan [package insert]. New York, NY: Pharmacia & Upjohn Company; 2014.

Geller RB et al. Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapyinduced diarrhea in bone marrow transplant and leukemia patients. Am J Hematol. 1995;50(3):167–172.

Cascinu S et al. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial.

J Clin Oncol. 1993;11(1):148–151.

Rosenoff SH et al. A multicenter, randomized trial of long-acting octreotide for the optimum prevention of

chemotherapy-induced diarrhea: results of the STOP trial. J Support Oncol. 2006;4(6):289–294.

Zachariah B et al. Octreotide acetate in prevention of chemoradiation-induced diarrhea in anorectal cancer:

randomized RTOG trial 0315. J Natl Cancer Inst. 2010;102(8):547–556.

Hoff PM et al. Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of

chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial. J Clin Oncol.

2014;32(10):1006–1011.

Andreyev J et al. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol.

2014;15(10):e447–460.

Payne AS et al. Dermatologic toxicity of chemotherapeutic agents. Semin Oncol. 2006;33(1):86–97.

Goolsby TV, Lombardo FA. Extravasation of chemotherapeutic agents: prevention and treatment. Semin Oncol.

2006;33(1):139–143.

Galimont-Collen AF et al. Classification and management of skin, hair, nail and mucosalside-effects of epidermal

growth factor receptor (EGFR) inhibitors. Eur J Cancer. 2007;43(5):845–851.

100.

Heidary N et al. Chemotherapeutic agents and the skin: An update. J Am Acad Dermatol. 2008;58(4):545–570.

Wang J et al. Protection against chemotherapy-induced alopecia. Pharm Res. 2006;23(11):2505–2514.

Karakunnel J et al. Hair loss. In: DeVita VT et al, eds. Cancer: Principles and Practice of Oncology. 9th ed.

Philadelphia, PA: Lippincott Williams & Wilkins; 2011:2368.

Grevelman EG, Breed WP. Prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol.

2005;16(3):352–358.

Shin H et al. Efficacy of interventions for prevention of chemotherapy-induced alopecia: a systematic review and

meta-analysis. Int J Cancer. 2015;136(5):E442–E454.

Capriotti K et al. The risk of nail changes with taxane chemotherapy: a systematic review of the literature and

meta-analysis. Br J Dermatol. 2015.

deMarinis M et al. Nail pigmentation with daunorubicin therapy. Ann Intern Med. 1978;89(4):516–517.

Shetty MR. Case of pigmented banding of the nail caused by bleomycin. Cancer Treat Rep. 1977;61(3):501–502.

Hrushesky WJ. Serpentine supravenous 5-fluorouracil (NSC-19893) hyperpigmentation. Cancer Treat Rep.

1976;60(5):639.

Fernandez-Obregon AC et al. Flagellate pigmentation from intrapleural bleomycin. A light microscopy and

electron microscopy study. J Am Acad Dermatol. 1985;13(3):464–468.

Horn TD et al. Observations and proposed mechanism of N,N′,N′-triethylenethiophosphoramide (thiotepa)-

induced hyperpigmentation. Arch Dermatol. 1989;125(4):524–527.

Harben DJ et al. Thiotepa-induced leukoderma. Arch Dermatol. 1979;115(8):973–974.

Vonderheid EC. Topical mechlorethamine chemotherapy. Considerations on its use in mycosis fungoides. Int J

Dermatol. 1984;23(3):180–186.

Wheeland RG et al. The flag sign of chemotherapy. Cancer. 1983;51(8):1356–1358.

Brzezniak C, Szabo E. Images in clinical medicine. Sunitinib-associated hair depigmentation. N Engl J Med.

2014;370(17):e27.

Lipworth AD et al. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on

sorafenib and sunitinib. Oncology. 2009;77(5):257–271.

Miller KK et al. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation,

etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71(4):787–794.

Ren Z et al. Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated

hand-foot skin reactions in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2015;33(8):894–900.

Hofheinz RD et al. Mapisal versus urea cream as prophylaxis for capecitabine-associated Hand-Foot syndrome: a

randomized phase III trial of the AIO Quality of Life Working Group. J Clin Oncol. 2015;33(22):2444–2449.

Lynch TJ Jr et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving

paradigm in clinical management. Oncologist. 2007;12(5):610–621.

Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung

cancer. Clin Lung Cancer. 2006;89(Suppl 1):S7–S14.

Cunningham D et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic

colorectal cancer. N EnglJ Med. 2004;351(4):337–345.

Liu G et al. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer

patients treated with gefitinib. Pharmacogenomics J. 2008;8(2):129–138.

Tan EH, Chan A. Evidence-based treatment options for the management of skin toxicities associated with

epidermal growth factor receptor inhibitors. Ann Pharmacother. 2009;43(10):1658–1666.

Pomerantz RG et al. Cutaneous reactions to epidermal growth factor receptor inhibitors. J Drugs Dermatol.

2010;9(10):1229–1234.

Lacouture ME et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated

dermatologic toxicities. Support Care Cancer. 2011;19(8):1079–1095.

Yeo W, Johnson PJ. Radiation-recallskin disorders associated with the use of antineoplastic drugs. Pathogenesis,

prevalence, and management. Am J Clin Dermatol. 2000;1(2):113–116.

Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol.

2001;59(3):237–245.

Kvols LK. Radiation sensitizers: a selective review of molecules targeting DNA and non-DNA targets. J Nucl

Med. 2005;46 Suppl 1:187S–190S.

Alley E et al. Cutaneous toxicities of cancer therapy. Curr Opin Oncol. 2002;14(2):212–216.

Kumar S et al. Management of skin toxicity during radiation therapy: a review of the evidence. J Med Imaging

Radiat Oncol. 2010;54(3):264–279.

.

.

.

.

.

.

.

.

.

110.

111.

112.

.

114.

115.

.

117.

.

.

120.

121.

122.

.

124.

.

.

127.

.

.

.

.

.

.

.

.

.

Bolderston A et al. The prevention and management of acute skin reactions related to radiation therapy: a

systematic review and practice guideline. Support Care Cancer. 2006;14(8):802–817.

Wyatt AJ et al. Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol.

2006;7(1):45–63.

Doellman D et al. Infiltration and extravasation: update on prevention and management. J Infus Nurs.

2009;32(4):203–211.

Boulanger J et al. Management of the extravasation of anti-neoplastic agents. Support Care Cancer.

2015;23(5):1459–1471.

Mouridsen HT et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two

prospective clinical multicentre studies. Ann Oncol. 2007;18(3):546–550.

Totect (dexrazoxane injection) [package insert]. Rockaway, NJ: Topo Target USA, Inc.; 2011.

Syrigou E et al. Acute hypersensitivity reactions to chemotherapy agents: an overview. Inflamm Allergy Drug

Targets. 2010;9(3):206–213.

Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor

oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794–7803.

Anderson T et al. Chemotherapy for testicular cancer: current status of the National Cancer Institute Combined

Modality Trial. Cancer Treat Rep. 1979;63(9/10):1687–1692.

Denis L. Anaphylactic reactions to repeated intravesical instillation with cisplatin. Lancet. 1983;1(8338):1378–

1379.

Getaz EP et al. Cisplatin-induced hemolysis. N EnglJ Med. 1980;302(6):334–335.

Levi JA, Aroney RS, Dalley DN. Haemolytic anaemia after cisplatin treatment. Br Med J (Clin Res Ed).

1981;282(6281):2003–2004.

Bacha DM et al. Phase I study of carboplatin (CBDCA) in children with cancer. Cancer Treat Rep.

1986;70(7):865–869.

Allen JC et al. Carboplatin and recurrent childhood brain tumors. J Clin Oncol. 1987;5(3):459–463.

Brunner KW, Young CW. A Methylhydrazine Derivative in Hodgkin’s Disease and Other Malignant

Neoplasms. Therapeutic and Toxic Effects Studied in 51 Patients. Ann Intern Med. 1965;63:69–86.

Glovsky MM et al. Hypersensitivity to procarbazine associated with angioedema, urticaria, and low serum

complement activity. J Allergy Clin Immunol. 1976;57(2):134–140.

Lokich JJ, Moloney WC. Allergic reaction to procarbazine. Clin Pharmacol Ther. 1972;13(4):573–574.

Jones SE et al. Hypersensitivity to procarbazine (Matulane) manifested by fever and pleuropulmonary reaction.

Cancer. 1972;29(2):498–500.

Arnold DJ, Stafford CT. Systemic allergic reaction to adriamycin. Cancer Treat Rep. 1979;63(1):150–151.

Solimando DA Jr, Wilson JP. Doxorubicin-induced hypersensitivity reactions. Drug Intell Clin Pharm.

1984;18(10):808–811.

Collins JA. Hypersensitivity reaction to doxorubicin. Drug Intell Clin Pharm. 1984;18(5):402–403.

Etcubanas E, Wilbur JR. Letter: Uncommon side effects of adriamycin (NSC-123127). Cancer Chemother Rep.

1974;58(6):757–758.

Crowther D et al. Management of adult acute myelogenous leukaemia. Br Med J. 1973;1(5846):131–137.

Tan CT, et al. Congenital atlanto-axial dislocation. Med J Malaysia. 1981;36(4):230–233.

Tan CT et al. Phase I trial of rubidazone (NSC 164011) in children with cancer. Med Pediatr Oncol.

1981;9(4):347–353.

Rosenfelt F et al. A fatal hyperpyrexial response to bleomycin following prior therapy: a case report and

literature review. Yale J Biol Med. 1982;55(5/6):529–531.

Leung WH et al. Fulminant hyperpyrexia induced by bleomycin. Postgrad Med J. 1989;65(764):417–419.

Bochner BS, Lichtenstein LM. Anaphylaxis. N EnglJ Med. 1991;324(25):1785–1790.

Rituxan (rituximab) [package insert]. South San Francisco, CA: Biogen Idec, Inc., and Genentech, Inc.; 2014.